April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Evolving Visual Results and Cost in Diabetic Macular Edema Treatment
Author Affiliations & Notes
  • Richard M Feist
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • Deepthi M Reddy
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • Richard M Feist
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • John O Mason
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • Martin L Thomley
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • Michael A Albert
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
    Ophthalmology, UAB, Birmingham, AL
  • Carrie E Huisingh
    Ophthalmology, UAB, Birmingham, AL
  • Natalie Price
    Research, Retina Consultants of Alabama, PC, Birmingham, AL
  • Footnotes
    Commercial Relationships Richard Feist, None; Deepthi Reddy, None; Richard Feist, None; John Mason, None; Martin Thomley, None; Michael Albert, None; Carrie Huisingh, None; Natalie Price, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1752. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Richard M Feist, Deepthi M Reddy, Richard M Feist, John O Mason, Martin L Thomley, Michael A Albert, Carrie E Huisingh, Natalie Price; Evolving Visual Results and Cost in Diabetic Macular Edema Treatment. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1752. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effect on clinical practice of the introduction of anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema.

Methods: Two cohorts with clinically significant diabetic macular edema were identified and studied retrospectively. One group began treatment 10 years prior to identification while the other began treatment 3 years prior to identification. Entry vision, final vision, and treatments were tabulated for each group. Treatment cost was calculated using current fee schedules for Medicare and the predominant private insurance carrier for the state of treatment (Alabama). A maximal and minimal cost model was built for both payer type and by anti-VEGF drug.

Results: Treatment in the 10-year-old cohort consisted entirely of laser photocoagulation while treatment in the 3-year-old cohort consisted of a combination of laser photocoagulation and anti-VEGF treatment. The 3 year cohort had fewer laser procedures (1.8 versus 2.4), better visual retention during 2 years of follow up (mean logMAR of visual loss 0.05 p=.32 versus 0.22 p<.0001 at 2 years follow up) and a higher mean treatment cost. Modeled treatment costs ranged from 7% to over 200% higher in the 3 year cohort. Pricing of the anti-VEGF medication was by far the strongest factor in cost differences among various treatment models.

Conclusions: Pharmacotherapy with anti-VEGF agents offers better visual prognosis for patients with clinically significant diabetic macular edema. This improved prognosis may come with a higher cost of treatment with drug costs composing most of the increase.

Keywords: 499 diabetic retinopathy • 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×